查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1600613

臨床試驗市場：依設計、階段、適應症分類 - 2025-2030 年全球預測

Clinical Trials Market by Design (Interventional Study, Observational Study), Phase (Phase I, Phase II, Phase III), Indication - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年臨床試驗市值為383億美元，預計到2024年將達到417.8億美元，複合年成長率為9.16%，預計到2030年將達到707.8億美元。

臨床試驗市場涵蓋人類藥物、設備和治療測試的所有階段，並作為開發平臺的關鍵組成部分，確保新治療方法在向公眾發布之前的有效性和安全性。臨床試驗的需求源於為監管核准提供必要資料並透過創新解決方案對抗不斷發展的疾病的需要。這些研究在製藥、生物技術和醫療設備業有著廣泛的應用，最終用途是醫院、研究機構和委外研發機構(CRO)。顯著影響成長的因素包括生物醫學研究的進步、慢性病的增加，以及人工智慧和機器學習等技術在試驗設計和資料收集中的整合。市場參與企業的新商機集中在分散臨床試驗（DCT）上，它利用遠端醫療和行動醫療技術來改善病患招募和保留。然而，市場成長受到高成本、嚴格的監管要求、道德問題以及管理複雜試驗設計的後勤挑戰的限制。為了利用創新和研究，相關人員將專注於整合數位健康工具，以簡化參與者的參與，並探索允許根據中間結果進行即時修改的自適應試驗設計。用於病患招募和現實世界證據收集的創新平台可以提高試驗效率和結果。此外，製藥公司、CRO 和技術提供者之間的夥伴關係可以促進試驗管理方面的資源和專業知識共用。競爭格局由全球和區域參與者組成，每位參與者都利用其獨特的能力來擴大其市場範圍。對這個充滿活力的市場的洞察表明，隨著精準醫學、基因組研究和特種藥物的發展勢頭持續成長。加強臨床試驗透明度和以患者為中心，同時策略性地駕馭監管環境，可以為臨床試驗領域的未來成長提供強力的道路。

主要市場統計
基準年[2023] 383億美元
預測年份 [2024] 417.8億美元
預測年份 [2030] 707.8億美元
複合年成長率（%） 9.16%

市場動態：揭示快速發展的臨床試驗市場的關鍵市場洞察

供需的動態交互作用正在改變臨床試驗市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 由於疾病盛行率上升和 CRO 整合而改善臨床試驗
    • 醫藥及生技製藥產業研發費用增加
    • 越來越關注學名藥和生技藥品的開發和商業化
  • 市場限制因素
    • 藥物開發成本增加，臨床研究專業人員短缺
  • 市場機會
    • 越來越關注藥物開發和以患者為中心的臨床試驗
    • 臨床試驗全球化與法規統一的進展
  • 市場挑戰
    • 嚴格的病患登記規定和跨境物流挑戰

波特五力：駕馭臨床試驗市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解臨床試驗市場的外部影響

外部宏觀環境因素在塑造臨床試驗市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解臨床試驗市場的競爭狀況

對臨床試驗市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣臨床試驗市場供應商的績效評估

FPNV定位矩陣是評估臨床試驗市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製臨床試驗市場的成功之路

臨床試驗市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 透過 CRO 整合增加疾病發生率並改善臨床試驗
      • 醫藥及生技製藥產業研發費用增加
      • 專注於學名藥和生技藥品的開發和商業化
    • 抑制因素
      • 藥物開發成本增加和臨床研究專業人員短缺
    • 機會
      • 加強對藥物開發的重視，將臨床試驗轉向以病人為中心
      • 臨床試驗的全球化和監管協調的進展
    • 任務
      • 嚴格的病患登記規定和跨境物流挑戰
  • 市場區隔分析
    • 設計：介入性和觀察性臨床試驗設計對於最佳化治療效果、風險和安全性評估的重要性
    • 階段：分階段實施臨床試驗，監測藥物代謝並收集初步資料
    • 適應症：一些建議對慢性疾病、心血管疾病和其他有害疾病進行適當治療方法和藥物治療的適應症。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 臨床試驗市場：設計

  • 干預研究
    • 自我調整臨床試驗
    • 非隨機對照試驗
    • 隨機對照試驗
  • 觀察性研究
    • 病例對照研究
    • 隊列研究
    • 橫斷面研究
    • 生態學研究

第7章 臨床試驗市場分階段

  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段

第8章 依適應症分類的臨床試驗市場

  • 自體免疫/發炎
  • 心血管
  • 中樞神經系統狀況
  • 糖尿病
  • 感染疾病
  • 肥胖
  • 腫瘤學
  • 疼痛管理

第9章美洲臨床試驗市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太臨床試驗市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東、非洲臨床試驗市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 柯爾伯格收購全球臨床試驗的多數股權
    • Arcanza 和 Reveles 合作擴大代表性不足社區的綜合臨床研究
    • 百時美施貴寶和楊森合作開始關鍵的 3 期 Librexia 臨床試驗計劃，評估口腔因子 XIa 抑制劑 Milbekian
  • 戰略分析和建議

公司名單

  • ProPharma Group Holdings, LLC
  • Charles River Laboratories International, Inc.
  • Accell Clinical Research, LLC
  • Congenix LLP
  • Parexel International Corporation
  • Qiagen NV
  • SGS SA
  • Bristol-Myers Squibb Company
  • Bio-Rad Laboratories, Inc.
  • SIRO Clinpharm Private Limited
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Clinipace
  • Atlant Clinical Ltd.
  • Quipment SAS
  • Labcorp
  • IQVIA Holdings, Inc.
  • Becton, Dickinson and Company
  • Merck KGaA
  • Eli Lilly and Company
  • Syneos Health, Inc.
  • Wuxi AppTec Inc.
  • Thermo Fisher Scientific Inc.
  • Icon PLC
  • Sartorius AG
  • Illumina, Inc
Product Code: MRR-434CCDA05152

The Clinical Trials Market was valued at USD 38.30 billion in 2023, expected to reach USD 41.78 billion in 2024, and is projected to grow at a CAGR of 9.16%, to USD 70.78 billion by 2030.

The clinical trials market encompasses all phases of drug, device, and treatment testing on human subjects, serving as a critical component in the development pipeline that assures the efficacy and safety of new therapies before they reach the public. The necessity of clinical trials arises from the need to combat evolving diseases with innovative solutions, providing vital data for regulatory approvals. These trials are broadly applicable across pharmaceutical, biotechnology, and medical device industries, with end-use in hospitals, research institutes, and contract research organizations (CROs). Significant growth influencers include advancements in biomedical research, increased prevalence of chronic diseases, and technological integration such as AI and machine learning in trial design and data collection. Emerging opportunities for market participants center around decentralized clinical trials (DCTs), which utilize telehealth and mobile health technologies to improve patient recruitment and retainment. However, market growth is constrained by high costs, stringent regulatory requirements, and ethical issues, along with logistical challenges in managing complex trial designs. To capitalize on innovation and research, stakeholders could focus on integrating digital health tools to streamline participant engagement or exploring adaptive trial designs that permit real-time modifications based on interim results. Innovative platforms for patient recruitment and real-world evidence collection can enhance trial efficiency and outcomes. Furthermore, developing partnerships between pharmaceutical companies, CROs, and technology providers can facilitate the sharing of resources and expertise in trial management. The competitive landscape comprises both global and regional players, each leveraging unique capabilities to expand market reach. Insight into this dynamic market suggests continual growth as precision medicine, genomic studies, and specialty pharmaceuticals gain momentum. Strategically navigating regulatory landscapes while enhancing trial transparency and patient centricity can offer a robust pathway for future growth in the clinical trials sector.

KEY MARKET STATISTICS
Base Year [2023] USD 38.30 billion
Estimated Year [2024] USD 41.78 billion
Forecast Year [2030] USD 70.78 billion
CAGR (%) 9.16%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Clinical Trials Market

The Clinical Trials Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of diseases and improved clinical trials due to CRO consolidation
    • Growing R&D expenditure of pharmaceutical and biopharmaceutical industry
    • Increased focus on the development and commercialization of generics and biologics
  • Market Restraints
    • Increased cost of drug development and lack of skilled clinical research professional
  • Market Opportunities
    • Increased focus on drug development and shift towards patient-centric clinical trials
    • Growing globalization of clinical trials and harmonization of regulations
  • Market Challenges
    • Stringent regulations for patient enrollment and cross-border logistics challenges

Porter's Five Forces: A Strategic Tool for Navigating the Clinical Trials Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Clinical Trials Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Clinical Trials Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Clinical Trials Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Clinical Trials Market

A detailed market share analysis in the Clinical Trials Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Clinical Trials Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Clinical Trials Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Clinical Trials Market

A strategic analysis of the Clinical Trials Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Clinical Trials Market, highlighting leading vendors and their innovative profiles. These include ProPharma Group Holdings, LLC, Charles River Laboratories International, Inc., Accell Clinical Research, LLC, Congenix LLP, Parexel International Corporation, Qiagen NV, SGS S.A., Bristol-Myers Squibb Company, Bio-Rad Laboratories, Inc., SIRO Clinpharm Private Limited, Novo Nordisk A/S, Pfizer Inc., Clinipace, Atlant Clinical Ltd., Quipment SAS, Labcorp, IQVIA Holdings, Inc., Becton, Dickinson and Company, Merck KGaA, Eli Lilly and Company, Syneos Health, Inc., Wuxi AppTec Inc., Thermo Fisher Scientific Inc., Icon PLC, Sartorius AG, and Illumina, Inc.

Market Segmentation & Coverage

This research report categorizes the Clinical Trials Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Design, market is studied across Interventional Study and Observational Study. The Interventional Study is further studied across Adaptive Clinical Trial, Non-randomized Control Trial, and Randomized Control Trial. The Observational Study is further studied across Case Control Study, Cohort Study, Cross Sectional Study, and Ecological Study.
  • Based on Phase, market is studied across Phase I, Phase II, Phase III, and Phase IV.
  • Based on Indication, market is studied across Autoimmune/Inflammation, Cardiovascular, CNS condition, Diabetes, Infectious Diseases, Obesity, Oncology, and Pain management.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of diseases and improved clinical trials due to CRO consolidation
      • 5.1.1.2. Growing R&D expenditure of pharmaceutical and biopharmaceutical industry
      • 5.1.1.3. Increased focus on the development and commercialization of generics and biologics
    • 5.1.2. Restraints
      • 5.1.2.1. Increased cost of drug development and lack of skilled clinical research professional
    • 5.1.3. Opportunities
      • 5.1.3.1. Increased focus on drug development and shift towards patient-centric clinical trials
      • 5.1.3.2. Growing globalization of clinical trials and harmonization of regulations
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulations for patient enrollment and cross-border logistics challenges
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Design: Importance of interventional and observational clinical trial design to optimize assessment of treatment efficacy, risk, and safety
    • 5.2.2. Phase: clinical trial phases in for monitoring drug metabolism and gathering initial data
    • 5.2.3. Indication: Several indications suggesting suitable treatments and medications for chronic, cardiovascular, and other harmful diseases
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Clinical Trials Market, by Design

  • 6.1. Introduction
  • 6.2. Interventional Study
    • 6.2.1. Adaptive Clinical Trial
    • 6.2.2. Non-randomized Control Trial
    • 6.2.3. Randomized Control Trial
  • 6.3. Observational Study
    • 6.3.1. Case Control Study
    • 6.3.2. Cohort Study
    • 6.3.3. Cross Sectional Study
    • 6.3.4. Ecological Study

7. Clinical Trials Market, by Phase

  • 7.1. Introduction
  • 7.2. Phase I
  • 7.3. Phase II
  • 7.4. Phase III
  • 7.5. Phase IV

8. Clinical Trials Market, by Indication

  • 8.1. Introduction
  • 8.2. Autoimmune/Inflammation
  • 8.3. Cardiovascular
  • 8.4. CNS condition
  • 8.5. Diabetes
  • 8.6. Infectious Diseases
  • 8.7. Obesity
  • 8.8. Oncology
  • 8.9. Pain management

9. Americas Clinical Trials Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Clinical Trials Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Clinical Trials Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Kohlberg Acquires Majority Stake in Worldwide Clinical Trials
    • 12.3.2. Alcanza and Reveles Partner to Expand Inclusive Clinical Research in Underrepresented Communities
    • 12.3.3. The Bristol Myers Squibb-Janssen Collaboration Launches Pivotal Phase 3 Librexia Clinical Trial Program Evaluating Milvexian, an Investigational Oral Factor XIa Inhibitor
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. ProPharma Group Holdings, LLC
  • 2. Charles River Laboratories International, Inc.
  • 3. Accell Clinical Research, LLC
  • 4. Congenix LLP
  • 5. Parexel International Corporation
  • 6. Qiagen NV
  • 7. SGS S.A.
  • 8. Bristol-Myers Squibb Company
  • 9. Bio-Rad Laboratories, Inc.
  • 10. SIRO Clinpharm Private Limited
  • 11. Novo Nordisk A/S
  • 12. Pfizer Inc.
  • 13. Clinipace
  • 14. Atlant Clinical Ltd.
  • 15. Quipment SAS
  • 16. Labcorp
  • 17. IQVIA Holdings, Inc.
  • 18. Becton, Dickinson and Company
  • 19. Merck KGaA
  • 20. Eli Lilly and Company
  • 21. Syneos Health, Inc.
  • 22. Wuxi AppTec Inc.
  • 23. Thermo Fisher Scientific Inc.
  • 24. Icon PLC
  • 25. Sartorius AG
  • 26. Illumina, Inc

LIST OF FIGURES

  • FIGURE 1. CLINICAL TRIALS MARKET RESEARCH PROCESS
  • FIGURE 2. CLINICAL TRIALS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CLINICAL TRIALS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CLINICAL TRIALS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CLINICAL TRIALS MARKET DYNAMICS
  • TABLE 7. GLOBAL CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CLINICAL TRIALS MARKET SIZE, BY ADAPTIVE CLINICAL TRIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CLINICAL TRIALS MARKET SIZE, BY NON-RANDOMIZED CONTROL TRIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CLINICAL TRIALS MARKET SIZE, BY RANDOMIZED CONTROL TRIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CLINICAL TRIALS MARKET SIZE, BY CASE CONTROL STUDY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CLINICAL TRIALS MARKET SIZE, BY COHORT STUDY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CLINICAL TRIALS MARKET SIZE, BY CROSS SECTIONAL STUDY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CLINICAL TRIALS MARKET SIZE, BY ECOLOGICAL STUDY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CLINICAL TRIALS MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CLINICAL TRIALS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CLINICAL TRIALS MARKET SIZE, BY CNS CONDITION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CLINICAL TRIALS MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CLINICAL TRIALS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CLINICAL TRIALS MARKET SIZE, BY OBESITY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL CLINICAL TRIALS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 80. CHINA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 84. INDIA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 85. INDIA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 89. INDONESIA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 90. INDONESIA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 94. JAPAN CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 95. JAPAN CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 99. MALAYSIA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 100. MALAYSIA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 104. PHILIPPINES CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 105. PHILIPPINES CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 109. SINGAPORE CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 110. SINGAPORE CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 114. SOUTH KOREA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 115. SOUTH KOREA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 119. TAIWAN CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 120. TAIWAN CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 124. THAILAND CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 125. THAILAND CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 129. VIETNAM CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 130. VIETNAM CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 140. DENMARK CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 141. DENMARK CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 145. EGYPT CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 146. EGYPT CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 150. FINLAND CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 151. FINLAND CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 155. FRANCE CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 156. FRANCE CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 160. GERMANY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 161. GERMANY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 165. ISRAEL CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 166. ISRAEL CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 170. ITALY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 171. ITALY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 175. NETHERLANDS CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 176. NETHERLANDS CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 180. NIGERIA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 181. NIGERIA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 185. NORWAY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 186. NORWAY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 190. POLAND CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 191. POLAND CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 195. QATAR CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 196. QATAR CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 200. RUSSIA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 201. RUSSIA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 205. SAUDI ARABIA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 206. SAUDI ARABIA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH AFRICA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 211. SOUTH AFRICA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 215. SPAIN CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 216. SPAIN CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 220. SWEDEN CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 221. SWEDEN CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 225. SWITZERLAND CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 226. SWITZERLAND CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 230. TURKEY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 231. TURKEY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED ARAB EMIRATES CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED ARAB EMIRATES CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 240. UNITED KINGDOM CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 241. UNITED KINGDOM CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 242. CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 243. CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2023